The American Pharmacist Pfizer assured this Friday that his vaccine against COVID-19 is effective in 90.7% in children with ages included between 5 and 11 years.
In a document published on the occasion of a meeting scheduled for next week with the United States Food and Drug Administration (FDA), the company explained that it has carried out a trial with around 2,000 minors.
Three of the minors who had been inoculated with the vaccine were infected, compared to 16 who contracted the disease in the group of children who had received a placebo. The company specified that twice as many children received the vaccine, compared to those who were injected with the placebo.
On October 7, Pfizer and BioNtech applied to the FDA for the authorization for emergency use of your COVID-19 vaccine in children ages five to eleven. So far the FDA only authorizes the use of this vaccine from the age of twelve.
Pharmaceutical companies Pfizer and BioNTech announced that the results of the latest clinical trials have generated a “robust” antibody response and that the vaccine is safe, which would bring closer the possibility of an infant serum available by the end of October or beginning of November.